FBXO22 is a potential therapeutic target for recurrent chondrosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Chondrosarcoma (CHS) is a malignant bone tumor resistant to conventional treatments.
• Recurrent CHS (Re-CHS) poses a significant clinical challenge due to poorly understood mechanisms.
• FBXO22 is implicated in various cancers, but its role in Re-CHS is unclear.

Purpose of the Study:

• To investigate the role of FBXO22 in recurrent chondrosarcoma.
• To explore the potential of FBXO22 and PD-L1 as therapeutic targets for Re-CHS.

Main Methods:

• Analysis of FBXO22 expression in clinical Re-CHS samples.
• In vitro experiments suppressing FBXO22 in CHS cells.
• Assessment of cell proliferation, migration, apoptosis, and PD-L1 expression.

Main Results:

• FBXO22 was highly expressed in clinical samples of Re-CHS.
• Suppression of FBXO22 reduced CHS cell proliferation and migration.
• FBXO22 inhibition facilitated CHS cell apoptosis and increased PD-L1 expression.

Conclusions:

• FBXO22 is a key factor in the progression of recurrent chondrosarcoma.
• Combined targeting of FBXO22 and PD-L1 presents a novel therapeutic strategy for Re-CHS.
• This approach may enhance immunotherapy for chondrosarcoma, particularly recurrent cases.